Lana Kupershmidt

Title: Lana Kupershmidt: Innovator in Cancer Treatment

Introduction

Lana Kupershmidt is a prominent inventor based in Kiryat Bialik, Israel. She has made significant contributions to the field of cancer treatment through her innovative research and patented inventions. With a total of 2 patents, her work focuses on developing therapies that address the challenges of cancer resistance.

Latest Patents

Lana's latest patents involve combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer. These patents provide a treatment method that utilizes a dual modulator of Insulin Receptor Substrate (IRS) and signal transducer and activator of transcription 3 (Stat3), along with other agents. The combination is designed to treat tumors that have developed resistance to various inhibitors, including EGFR inhibitors, EGFR antibodies, mTOR inhibitors, MEK inhibitors, and mutated B-Raf inhibitors. Additionally, her work aims to prevent acquired resistance of tumors to these agents and to reduce the risk of tumor recurrence after treatment cessation. Furthermore, her patents also explore combination therapy that includes an immunotherapy agent to sensitize tumors to immunotherapy.

Career Highlights

Throughout her career, Lana has worked with notable companies such as Tyrnovo Ltd. and Technion Research & Development Foundation Ltd. Her experience in these organizations has allowed her to advance her research and contribute to the development of innovative cancer treatments.

Collaborations

Lana has collaborated with esteemed colleagues, including Izhak Haviv and Hadas Reuveni, to further her research and enhance the impact of her inventions.

Conclusion

Lana Kupershmidt is a dedicated inventor whose work in cancer treatment is paving the way for new therapeutic options. Her innovative approach to addressing treatment resistance highlights her commitment to improving patient outcomes in oncology.